CN116098937A - 牡丹籽油在脑缺血再灌注损伤保护中的应用 - Google Patents
牡丹籽油在脑缺血再灌注损伤保护中的应用 Download PDFInfo
- Publication number
- CN116098937A CN116098937A CN202211536955.XA CN202211536955A CN116098937A CN 116098937 A CN116098937 A CN 116098937A CN 202211536955 A CN202211536955 A CN 202211536955A CN 116098937 A CN116098937 A CN 116098937A
- Authority
- CN
- China
- Prior art keywords
- group
- seed oil
- peony seed
- cerebral
- ischemia reperfusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000015112 vegetable and seed oil Nutrition 0.000 title claims abstract description 66
- 241000736199 Paeonia Species 0.000 title claims abstract description 55
- 235000006484 Paeonia officinalis Nutrition 0.000 title claims abstract description 55
- 206010008118 cerebral infarction Diseases 0.000 title claims abstract description 41
- 201000006474 Brain Ischemia Diseases 0.000 title claims abstract description 24
- 206010008120 Cerebral ischaemia Diseases 0.000 title claims abstract description 24
- 206010063837 Reperfusion injury Diseases 0.000 title claims abstract description 21
- 230000004224 protection Effects 0.000 title claims abstract description 13
- 210000002569 neuron Anatomy 0.000 claims abstract description 25
- 230000010410 reperfusion Effects 0.000 claims abstract description 21
- 230000006378 damage Effects 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 16
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 15
- 208000028867 ischemia Diseases 0.000 claims abstract description 15
- 210000005036 nerve Anatomy 0.000 claims abstract description 13
- 239000008158 vegetable oil Substances 0.000 claims abstract description 12
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 10
- 208000014674 injury Diseases 0.000 claims abstract description 10
- 208000006752 brain edema Diseases 0.000 claims abstract description 5
- 206010048962 Brain oedema Diseases 0.000 claims abstract description 4
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 15
- 230000002490 cerebral effect Effects 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 11
- 210000004556 brain Anatomy 0.000 claims description 9
- 230000000302 ischemic effect Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000003064 anti-oxidating effect Effects 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000010408 film Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract description 10
- 230000036542 oxidative stress Effects 0.000 abstract description 5
- 230000006654 negative regulation of apoptotic process Effects 0.000 abstract description 4
- 230000005779 cell damage Effects 0.000 abstract description 2
- 208000037887 cell injury Diseases 0.000 abstract description 2
- 230000028709 inflammatory response Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 51
- 210000005013 brain tissue Anatomy 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 12
- 101100366137 Mesembryanthemum crystallinum SODCC.1 gene Proteins 0.000 description 11
- 101100096142 Panax ginseng SODCC gene Proteins 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 101150017120 sod gene Proteins 0.000 description 11
- 238000011282 treatment Methods 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 7
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 6
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 6
- 210000000805 cytoplasm Anatomy 0.000 description 6
- 102100032912 CD44 antigen Human genes 0.000 description 5
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 210000000269 carotid artery external Anatomy 0.000 description 5
- 210000003710 cerebral cortex Anatomy 0.000 description 5
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000007971 neurological deficit Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211536955.XA CN116098937B (zh) | 2022-12-02 | 2022-12-02 | 牡丹籽油在脑缺血再灌注损伤保护中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211536955.XA CN116098937B (zh) | 2022-12-02 | 2022-12-02 | 牡丹籽油在脑缺血再灌注损伤保护中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116098937A true CN116098937A (zh) | 2023-05-12 |
CN116098937B CN116098937B (zh) | 2024-06-14 |
Family
ID=86262892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211536955.XA Active CN116098937B (zh) | 2022-12-02 | 2022-12-02 | 牡丹籽油在脑缺血再灌注损伤保护中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116098937B (zh) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101649246A (zh) * | 2009-09-07 | 2010-02-17 | 兰州牡丹园艺开发公司 | 一种提取及精制紫斑牡丹籽油的方法 |
CN101653429A (zh) * | 2009-09-07 | 2010-02-24 | 甘肃中川牡丹研究所 | 一种从紫斑牡丹籽中提取α-亚麻酸制成软胶囊的方法 |
CN101711579A (zh) * | 2009-12-06 | 2010-05-26 | 兰州牡丹园艺开发公司 | 紫斑牡丹胶囊 |
CN102851112A (zh) * | 2012-09-07 | 2013-01-02 | 乔新光 | 一种富硒牡丹籽精油的制取方法 |
CN104000196A (zh) * | 2014-06-04 | 2014-08-27 | 李�杰 | 复方牡丹籽油制剂,及制备方法和应用 |
CN106214768A (zh) * | 2016-09-06 | 2016-12-14 | 郑州师范学院 | 一种牡丹籽油虾青素复合物及其应用 |
CN106376933A (zh) * | 2016-08-30 | 2017-02-08 | 昆明酷特利生物科技有限公司 | 一种健脑抗氧化保健品及其应用 |
CN106900885A (zh) * | 2017-02-27 | 2017-06-30 | 山东省科学院生物研究所 | 一种微囊化牡丹籽油、复配组合物及其制备方法 |
CN107987955A (zh) * | 2017-11-27 | 2018-05-04 | 余雪平 | 一种牡丹籽油的加工方法 |
CN109452436A (zh) * | 2018-10-25 | 2019-03-12 | 河南九九生物科技有限公司 | 一种牡丹籽油凝胶糖果及其制备方法 |
-
2022
- 2022-12-02 CN CN202211536955.XA patent/CN116098937B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101649246A (zh) * | 2009-09-07 | 2010-02-17 | 兰州牡丹园艺开发公司 | 一种提取及精制紫斑牡丹籽油的方法 |
CN101653429A (zh) * | 2009-09-07 | 2010-02-24 | 甘肃中川牡丹研究所 | 一种从紫斑牡丹籽中提取α-亚麻酸制成软胶囊的方法 |
CN101711579A (zh) * | 2009-12-06 | 2010-05-26 | 兰州牡丹园艺开发公司 | 紫斑牡丹胶囊 |
CN102851112A (zh) * | 2012-09-07 | 2013-01-02 | 乔新光 | 一种富硒牡丹籽精油的制取方法 |
CN104000196A (zh) * | 2014-06-04 | 2014-08-27 | 李�杰 | 复方牡丹籽油制剂,及制备方法和应用 |
CN106376933A (zh) * | 2016-08-30 | 2017-02-08 | 昆明酷特利生物科技有限公司 | 一种健脑抗氧化保健品及其应用 |
CN106214768A (zh) * | 2016-09-06 | 2016-12-14 | 郑州师范学院 | 一种牡丹籽油虾青素复合物及其应用 |
CN106900885A (zh) * | 2017-02-27 | 2017-06-30 | 山东省科学院生物研究所 | 一种微囊化牡丹籽油、复配组合物及其制备方法 |
CN107987955A (zh) * | 2017-11-27 | 2018-05-04 | 余雪平 | 一种牡丹籽油的加工方法 |
CN109452436A (zh) * | 2018-10-25 | 2019-03-12 | 河南九九生物科技有限公司 | 一种牡丹籽油凝胶糖果及其制备方法 |
Non-Patent Citations (1)
Title |
---|
C. HEURTEAUX ET AL.: "ALPHA-LINOLENIC ACID AND RILUZOLE TREATMENT CONFER CEREBRAL PROTECTION AND IMPROVE SURVIVAL AFTER FOCAL BRAIN ISCHEMIA", 《NEUROSCIENCE》, pages 241 * |
Also Published As
Publication number | Publication date |
---|---|
CN116098937B (zh) | 2024-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101203270B (zh) | 具有体重再分配性能的物质 | |
Ge et al. | Effects of high fluoride and low iodine on brain histopathology in offspring rats | |
CN109528742B (zh) | 松果菊苷作为治疗新生儿缺氧缺血性脑病的制药用途 | |
CN116098937B (zh) | 牡丹籽油在脑缺血再灌注损伤保护中的应用 | |
CN110354171A (zh) | 一种含大麻叶提取物的宠物外用软膏及其制备方法 | |
KR101771695B1 (ko) | 스피루리나 추출물을 유효성분으로 함유하는 비만 예방 및 치료용 약학적 조성물 | |
CN113476321A (zh) | 一种用异甜菊醇制备皮肤美白和抗黑色素生成的化妆品制剂的应用 | |
CN102114170B (zh) | 防治心肌缺血再灌注损伤的中药组合物及其制备方法 | |
CN102333527B (zh) | 用于预防和延迟色素性视网膜炎的丝氨酸棕榈酰转移酶抑制剂 | |
CN106389740A (zh) | 一种预防和/或延缓老年轻度认知障碍的组合物及其使用方法 | |
CN103977014B (zh) | 一种应用于治疗代谢综合征的药物 | |
KR101938056B1 (ko) | 개꼬시래기 추출물 또는 분획물을 유효성분으로 함유하는 당뇨병의 예방 및 치료용 약학 조성물 | |
CN100387294C (zh) | 一种药物组合物及其制备方法和质量控制方法 | |
CN109966373A (zh) | 一种黑果枸杞籽油提取物在降血脂药物中的应用 | |
CN105193795A (zh) | 两种卤酚化合物在促血管生成作用方面的应用 | |
CN104000813A (zh) | 槲皮素对糖尿病性白内障的防治作用 | |
JP2016013991A (ja) | 抗子宮筋腫用の漢方薬草合成物およびその抽出物の用途 | |
CN109276688B (zh) | 一种用于老年痴呆症的中药组合物 | |
KR20180080834A (ko) | 톳 추출물을 포함하는 항염증성 및 염증성 신경퇴행성 질환 예방 또는 치료용 조성물 | |
Shokan et al. | Effects of Rumex tianschanicus Losinsk extract on hematological indicators in experimental gastritis | |
CN104473915B (zh) | 西维来司他作为治疗癫痫病药物的应用 | |
CN110250526A (zh) | 一种具有辅助降血脂功能的保健食品及其制备方法 | |
CN110038071A (zh) | 一种具有抗疱疹病毒的中药组合物及制备方法和应用 | |
CN109157548A (zh) | 一种具有抗疲劳和壮阳功能的组合物及制备方法 | |
CN115645449B (zh) | 一种双辅料酒蜜制山萸肉炮制方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240514 Address after: 274000 Yaoshun peony Industrial Park, Heze City, Shandong Province (east of Heze Peony Office) Applicant after: HEZE YAO AND SHUN PEONY BIOTECHNOLOGY CO.,LTD. Country or region after: China Applicant after: Heze branch of Shandong Academy of Sciences Address before: Heze Campus (Branch) of Qilu University of Technology (Shandong Academy of Sciences), No. 1999, Mount Taishan Road, Mudan District, Heze City, Shandong Province, 274000 Applicant before: Heze branch of Shandong Academy of Sciences Country or region before: China |
|
GR01 | Patent grant | ||
GR01 | Patent grant |